肺癌并发肺栓塞的危险因素及预后分析

来源期刊：广州医药 | 40-45 发布时间：2021-11-25 收稿时间：2025/11/13 18:11:46 阅读量：7

作者：: 罗水妹,

许白兰,

沈冰寒,

黄颂平,

关键词：: 肺癌肺栓塞中位生存期预后危险因素; Lung cancer Pulmonary embolism Overall survival Prognosis Risk factors

DOI：: 10.3969/j.issn.1000-8535.2021.02.009

收稿时间：: 2020-08-12
修订日期：
接收日期：
引用总数：: 0

目的本研究旨在探讨肺癌合并肺栓塞的相关危险因素及肺栓塞对肺癌患者预后的影响。方法检索2000年1月—2020年3月万方、中国知网、维普期刊、Medline Pubmed及EMBASE数据库中所有相关文献,并使用RevMan 5.3软件进行统计分析。结果 9项临床病例对照研究共1 179例患者纳入本研究。分析结果显示肺癌合并肺栓塞患者的中位生存时间明显低于单纯肺癌患者(HR=2.82,95%CI[2.06,3.87],P＜0.000 1)。危险因素分析显示腺癌发生肺栓塞的风险高于非腺癌(比值比(OR)=3.07, P＜0.000 1),III-IV期患者发生肺栓塞的风险明显高于I-II期患者(OR=2.97,P＜0.000 1),D-二聚体水平高的患者发生肺栓塞的风险是正常患者的4.32倍(P<0.000 1),白细胞(WBC) >11×109/L的患者发生肺栓塞的风险是WBC≤11×109/L患者的6.62倍(P＜0.000 1)。化疗史和中心静脉置管显著增加肺栓塞风险,OR值分别为3.02 (P＜0.000 1)和2.30 (P＜0.000 1)。然而,吸烟史、饮酒史、性别、糖尿病、COPD、高血压病等临床因素与肺栓塞发生无统计学相关性。结论肺栓塞的发生明显影响肺癌患者的预后,其相关的危险因素为病理类型、分期、化疗史、中心静脉导管置入史、D-二聚体升高、白细胞＞11×10⁹/L。

Objective To investigate the risk factors of developing pulmonary embolism and its influence on the prognosis of lung cancer patients. Methods The following databases such as Wanfang Database, China National Knowledge Infrastructure (CNKI), Chinese Weipu Database, Medline Pubmed and EMBASE were searched to identify relevant articles which were published during January 2000 to March 2020. Statistical analysis was performed using RevMan 5.3 software. Results 9 controlled trials incorporating 1 179 patients were included in this study. The results showed that the overall survival of lung cancer patients complicated with pulmonary embolism was significantly lower than that of lung cancer patients without pulmonary embolism (HR=2.82, 95%CI[2.06,3.87], P<0.000 1). The analysis on risk factors of developing pulmonary embolism showed that adenocarcinoma had a higher risk of pulmonary embolism than non-adenocarcinoma with Odds Ratio (OR)=3.07 (P<0.000 1). Patients in stage III-IV encountered significantly higher risk of pulmonary embolism than those in stage I-II (OR=3.07,P<0.000 1). Furthermore, the risk of pulmonary embolism in patients with high level of D-dimer was 4.32 times higher than in normal patients (P<0.000 1), and 6.62 times higher than those with WBC ≤11×10⁹/L (P<0.000 1). Additionally, the history of chemotherapy and central venous catheterization significantly increased the risk of pulmonary embolism, with OR of 3.02 (P<0.000 1) and 2.30 (P<0.000 1), respectively. However, smoking, alcohol consumption, gender, diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular disease, hypertension were not statistical correlated with the occurrence of pulmonary embolism in lung cancer patients. Conclusion The occurrence of pulmonary embolism significantly affects the prognosis of patients with lung cancer, and the related risk factors were pathological type, stage, chemotherapy, central venous catheterization, increased D-dimer level, and WBC>11×10⁹/L.

1、 LUZZATTO G, SCHAFER A I. Theprethrombotic state in cancer[J]. Semin in Oncol, 1990, 17(2):147-159.

2、 KHORANA, A A. Thromboembolism in hospitalized neutropenic cancer patients[J]. J Clin Oncol, 2006, 24(3):484-490.

3、 KOBAYASHI Y, NAKADA J, KURODA H, et al. Spinal epidural hematoma during anticoagulant therapy for pulmonary embolism: postoperative complications in a patient with lung cancer [J]. Ann Thorac Cardiovasc Surg, 2014, 20(Suppl):493-496.

4、 KHORANA A A, FRANCIS C W, CULAKOVA E,et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy [J]. J Thromb Haemost, 2007, 5(3):632-634.

5、 GEERTS W H, BERGQVIST D, PINEO G F, et al. Prevention of venous thromboembolism: American college of chest physicians evidence based clinical practice guidelines (8th edition) [J]. Chest, 2008, 133(6 Suppl): 381S-453S.

6、 WANG Z,YAN H H,YANG J J,et al. Venous thrombolism risk factors in Chinese non-small cell lung cancer patients [J]. Support Care Cancer, 2015, 23(3):635-641.

7、 FOX E A, KAHN S R. The relationship between inflammation and venous thrombosis. a systematic review of clinical studies [J]. Thromb Haemost, 2005, 94(2):362-365.

8、 SULLIVAN V V, HAWLEY A E, FARRIS D M, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice [J]. J Surg Res, 2003, 109(1):1-7.

9、 IRENE C, GREGORY Y H. Virchow's triad revisited: blood constituents [J]. Pathophysiol Haemost Thromb, 2003, 33(5-6):449-454.

10、 HEIT J A, SILVERSTEIN M D, MOHR D N, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study [J]. Arch Int Med, 2000, 160(6):809-815.

11、郑红霞,马彩霞,王敬东. 肺血栓栓塞患者血浆D-二聚体测定的临床意义[J],实用医药杂志,2007,24(7):824-824.

12、 SORENSEN H T, MELLEMKJAER L, OLSEN J H, et al. Prognosis of cancers associated with venous thromboembolism [J]. N Engl J Med, 2000, 343(25):1846-1850.

13、 MA L, WEN Z. Risk factors and prognosis of pulmonary embolism in patients with lung cancer[J].Med, 2017, 96(16):e6638-e6640.

14、石宗华, 师广勇, 孙哲,等. 肺癌合并肺栓塞危险因素的病例对照研究[J],中华肿瘤防治杂志,2015,22(11):863-866.

15、孙薇,王海燕,文仲光,等. 肺癌并发肺栓塞患者的临床特征[J].中华结核和呼吸杂志,2016,39(3):198-202.

16、纳建荣,马宣,周玮. 原发性肺癌合并肺栓塞的临床特征分析[J].临床肺科杂志,2017,22(5):817-820.

17、唐开华. 肺癌合并肺栓塞危险因素及预后的临床分析[J].临床肺科杂志,2017,22(8):1477-1480.

18、邱子珑. 肺癌合并静脉血栓栓塞危险因素及预后的临床分析[D].石家庄:河北医科大学,2016.

19、 CUMPSTON M, LI T, PAGE M J, CHANDLER J, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions [J]. Cochrane Database Syst Rev, 2019, 3(10):Ed000142-Ed000157.

20、张琳. 肺癌合并肺栓塞的临床预后及其相关危险因素分析[J].海南医学,2015,26(11):44-46.

21、王峻,周卫华,许林,等. 肺癌合并肺栓塞危险因素及预后的临床分析[J].中国肺癌杂志,2011,14(10):780-784.

22、李娜,王燕. 23例肺癌并发肺栓塞的临床分析[J].中国肺癌杂志,2014,17(3):254-259.

23、 CONNOLLY G C, KHORANA A A. Risk stratification for cancer-associated venous thromboembolism [J]. Best Prac Res Clin Haematol, 2009, 22(1):35-47.

24、 KORTE W. Cancer and thrombosis: an increasingly important association [J]. Support Care Cancer, 2008, 16(3):223-228.

25、 MOLINA J R, YANG P, CASSIVI S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J]. Mayo Clin Proc, 2008, 83(5):584-594.

26、 ZHANG J, GOLD K A, LINH Y, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry [J]. J Thorac Oncol, 2015, 10(4):682-690.